2seventy bio, Inc. - Common Stock (NQ:TSVT)

5.000 UNCHANGED

Last Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about 2seventy bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum ↗

January 11, 2022

2seventy bio Inc's (NASDAQ: TSVT) anti-BCMA CAR-T got axed as part of a corporate update. The treatment was under development in collaboration with Bristol...

Via Benzinga

2seventy bio Shares Key Milestones and Business Updates for 2022

January 11, 2022

From 2seventy bio, Inc.

Via Business Wire

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

January 06, 2022

From 2seventy bio, Inc.

Via Business Wire

3 Best Performing Healthcare IPOs in 2021 ↗

December 28, 2021

Healthcare IPOs, 2seventy bio, Inc., Regencell Bioscience Holdings Limited, and Biofrontera Inc. have generated significant returns since their stock market debut and could be ideal additions to one’s...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗

January 06, 2022

Upgrades For Canada Goose Holdings Inc (NYSE:

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 05, 2022

Before 10 am on Wednesday, 99 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: Sea (NYSE:SE) was the largest firm by market cap to set a...

Via Benzinga

2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting

December 13, 2021

From 2seventy bio, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

December 03, 2021

Gainers Celyad Oncology (NASDAQ:CYAD) shares rose 22.75% to $4.37 during Friday's pre-market session. The company's market cap stands at $70.3 million. Biolase (...

Via Benzinga

2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

December 01, 2021

From 2seventy bio, Inc.

Via Business Wire

41 Stocks Moving In Monday's Mid-Day Session ↗

November 15, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares climbed 87.1% to $6.64 after the company agreed to be acquired by Durational Capital Management. The company also reported Q3...

Via Benzinga

2seventy bio to Present at the 5th Annual Cowen IO Next Summit

November 10, 2021

From 2seventy bio, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗

November 08, 2021

Upgrades For Nektar Therapeutics (NASDAQ:

Via Benzinga

64 Biggest Movers From Yesterday ↗

November 09, 2021

Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile...

Via Benzinga

2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

November 04, 2021

From 2seventy bio, Inc.

Via Business Wire

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

64 Stocks Moving In Friday's Mid-Day Session ↗

November 05, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...

Via Benzinga

2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company

November 04, 2021

From 2seventy bio, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.